ICMH
HUMAW icon

Integrity Capital Management (HK)’s Humacyte Inc Warrant HUMAW Stock Holding History

Integrity Capital Management (HK)’s Portfolio HUMAW Stock Details HUMAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,830
Closed -$36K – 193
2021
Q4 		$36K Buy
+15,830
New +$46.3K 0.11% 175

Other funds holding HUMAW

CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $30.4M AUM 3.41% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32M AUM 108.13% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.24B AUM 137.67% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $244M AUM 110.95% 1-Year Est. Return

Integrity Capital Management (HK)'s HUMAW Position: Q1 2022 in Review

Integrity Capital Management (HK) sold out of Humacyte Inc Warrant (HUMAW) in Q1 2022, closing a stake of 15,830 shares — an estimated $36K sold.

Integrity Capital Management (HK) first reported a position in HUMAW in Q4 2021 and held it in 1 quarter. The position peaked at $36K in Q4 2021. 12 funds tracked by Wall St. Rank hold HUMAW as of Q1 2022.

  • Integrity Capital Management (HK) reported no remaining Humacyte Inc Warrant position as of Q1 2022 after selling out during the quarter.
  • Integrity Capital Management (HK) sold 15,830 Humacyte Inc Warrant shares in Q1 2022, an estimated $36K.
  • Integrity Capital Management (HK) first reported a position in Humacyte Inc Warrant in Q4 2021 and held it in 1 quarter.
  • Integrity Capital Management (HK)'s Humacyte Inc Warrant position peaked at $36K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Humacyte Inc Warrant as of Q1 2022.

Based on Integrity Capital Management (HK)'s 13F filing for Q1 2022, filed 26 Apr 2022.